Payment overview · 2025
General Payments
$499.86
29 reported records · 16 companies
Healthcare provider profile · identity verified
Cheri Conley Johnston, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KNOXVILLE, TN · NPI 1639186455
Verified facts
What the public records show
CMS Open Payments records show Cheri Conley Johnston, M.D. received $499.86 in general payments during 2025 across 29 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.29 | 16.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.25 | 12.8% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $56.11 | 11.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.79 | 9.8% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $41.49 | 8.3% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $34.92 | 7.0% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.55 | 5.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $21.27 | 4.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $19.55 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.21 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.45 | 3.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.26 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.90 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.77 | 2.8% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $9.20 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.01 | 28 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $80.29 | 5 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $56.11 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $56.11 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.79 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $34.92 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $26.55 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $9.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 458 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 107 |
| Losartan Potassium | Losartan Potassium | 212 | 64 |
| Lisinopril | Lisinopril | 191 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 169 | 58 |
| Omeprazole | Omeprazole | 145 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 43 |
| Metformin Hcl Er | Metformin Hcl | 129 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 40 |
| Simvastatin | Simvastatin | 107 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 40 |
| Potassium Chloride | Potassium Chloride | 97 | 32 |
| Montelukast Sodium | Montelukast Sodium | 85 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 20 |
| Sertraline Hcl | Sertraline Hcl | 81 | 26 |
| Gabapentin | Gabapentin | 79 | 28 |
| Metformin Hcl | Metformin Hcl | 75 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 23 |
| Furosemide | Furosemide | 64 | 26 |
| Ozempic | Semaglutide | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 17 |
| Allopurinol | Allopurinol | 53 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Trazodone Hcl | Trazodone Hcl | 51 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 15 |
| Eliquis | Apixaban | 46 | 13 |
| Atenolol | Atenolol | 43 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Famotidine | Famotidine | 40 | 14 |
| Meloxicam | Meloxicam | 40 | 15 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 14 |
| Estradiol | Estradiol | 32 | 14 |
| Carvedilol | Carvedilol | 31 | 14 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 26 |
| Alprazolam | Alprazolam | 28 | 13 |
| Azithromycin | Azithromycin | 28 | 25 |
| Methocarbamol | Methocarbamol | 28 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 11 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Levofloxacin | Levofloxacin | 22 | 13 |
| Cefdinir | Cefdinir | 21 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 11 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Baclofen | Baclofen | 13 | suppressed |
| Lyllana | Estradiol | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $499.86 · 29 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AMVUTTRA, APTIMA, BREZTRI, ELIQUIS, FARXIGA, FUROSCIX, JARDIANCE, Kerendia, LifeVest, NEXLETOL, OPSUMIT, OPSYNVI, OTEZLA, REPATHA, RHYTHM EXPRESS, THINPREP 2000 PROCESSOR, UPTRAVI, VERQUVO, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error